Biologic & Biosimilar RA Drugs Market Report 2025

The biologic & biosimilar ra drugs market size has grown strongly in recent years. It will grow from $13.99 billion in 2024 to $14.71 billion in 2025 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to market adoption rates, clinical trial outcomes, market share changes, long-term patient outcomes, pricing strategies.

The biologic & biosimilar ra drugs market size is expected to see strong growth in the next few years. It will grow to $19.51 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to increasing biologic drug development, market competition, healthcare policies, patient preferences, clinical research & development. Major trends in the forecast period include rise in biosimilar market competition, personalized medicine and precision therapy, advancements in drug delivery systems, focus on safety and efficacy, patient-centric healthcare.

The growing older population and the rising incidence of rheumatoid arthritis are propelling the biologics and biosimilar RA drugs market. The older population consists of individuals aged 60 years and above, and rheumatoid arthritis is an autoimmune condition where the immune system mistakenly attacks healthy cells, primarily affecting the joints. This disease is more prevalent in older adults, as aging weakens the immune system. Biologics and biosimilar RA drugs are particularly effective in treating rheumatoid arthritis compared to conventional medications. For example, the World Health Organization (WHO), a specialized health agency of the United Nations based in Switzerland, reported that in 2020, there were approximately 1 billion people aged 60 and over globally, with projections estimating this number will rise to 1.4 billion by 2030 and 2.1 billion by 2050. Additionally, the Centers for Disease Control and Prevention (CDC), a US-based public health agency, anticipates that the number of adults with arthritis in the USA will increase to 78.4 million by 2040, with 34.6 million experiencing activity limitations due to arthritis. Thus, the combination of a growing geriatric population and increasing cases of rheumatoid arthritis is driving the biologics and biosimilars RA drugs market forward.

Anticipated growth in healthcare spending is poised to drive the expansion of the biologic and biosimilar RA drug market. Healthcare spending encompasses the total financial outlay by individuals, governments, and organizations on medical goods and services, encompassing expenses related to health condition prevention, treatment, and management. Biologic and biosimilar RA drugs play a pivotal role in optimizing the management of rheumatoid arthritis by providing specialized and often costly treatments in a cost-effective manner. For instance, projections by the Canada-based Institute for Health Information (CIHI) indicate that total health spending in Canada is expected to reach $344 billion in 2023, amounting to $8,740 per Canadian. This represents a 2.8% growth in 2023, following a 1.5% increase in 2022. The escalating healthcare spending landscape is a key driver for the biologic and biosimilar RA drug market.

A prominent trend contributing to popularity is the introduction of new innovations in the biologic and biosimilar RA drugs market. Major industry players are concentrating on the development of biosimilar treatments, exemplified by advancements such as Dual Concentration Biosimilar Options, offering cost-effective alternatives. Noteworthy is the collaboration between Organon, a US-based healthcare company, and Samsung Bioepis, a South Korea-based biopharmaceutical company. In July 2023, they launched HADLIMA, a biosimilar of Humira (adalimumab), in the US. HADLIMA, available in both high and low concentrations, aims to improve accessibility and affordability for patients with autoimmune diseases. Priced at an 85% discount to Humira, HADLIMA includes an autoinjector endorsed by the Arthritis Foundation and a patient support program called 'HADLIMA For You,' providing educational resources and co-pay support. Indicated for various conditions including rheumatoid arthritis and Crohn's disease, HADLIMA, with its dual concentration options, ensures seamless continuity of care for patients.

Leading companies in the biologic and biosimilar RA drugs market are securing approvals for groundbreaking biologics, including injectable medications, to enhance their offerings for the treatment of polymyalgia rheumatica. Injectable medications, typically administered in liquid form using a needle and syringe, are gaining prominence in expanding treatment options. For instance, in February 2023, Regeneron Pharmaceuticals, Inc., a US-based biotechnology company, and Sanofi, a France-based healthcare and pharmaceutical company, obtained FDA approval for Kevzara (sarilumab) to address polymyalgia rheumatica (PMR) in adults with an inadequate response to corticosteroids or those unable to tolerate corticosteroid taper. The approval stems from positive outcomes in the SAPHYR Phase 3 trial, where Kevzara demonstrated a significant 28% sustained remission rate compared to the placebo's 10% at 52 weeks. Originally approved for rheumatoid arthritis, Kevzara stands out as the first and only biologic treatment for PMR, providing relief from its debilitating symptoms.

In November 2022, Biocon, an India-based biopharmaceutical company, completed the acquisition of Viatris' global biosimilars business for $3 billion. This acquisition serves to bring patients, consumers, and payors closer to Biocon Biologics, offering direct commercial capabilities and supporting infrastructure across various emerging and advanced markets. Viatris, a US-based pharmaceutical company, specializes in manufacturing biosimilars for treating rheumatoid arthritis and other diseases. The acquisition positions Biocon Biologics to strengthen its presence and expand its reach in the biosimilars business, further solidifying its standing in the competitive landscape.

Major companies operating in the biologic & biosimilar RA drugs market include Samsung BioLogics Co. Ltd., Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC., Teva Pharmaceutical Industries Ltd., Fresenius Se & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., Gedeon Richter Plc., La Roche Ltd., Regeneron Pharmaceuticals Inc., Bristol-Myers Squibb Company, Dr. Reddy's Laboratories Ltd., Biogen Inc., Genentech Inc., GlaxoSmithKline plc, Mylan N.V., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Biocon Ltd., Coherus BioSciences Inc.

North America was the largest region in the biologic & biosimilar RA drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in the biologic & biosimilar ra drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biologic & biosimilar ra drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Biologics and biosimilars belong to a drug category derived from living organisms such as cells, microorganisms, and other living entities. Biosimilars are specifically designed to closely resemble an already approved biological drug. These medications are primarily used to treat rheumatoid arthritis (RA), a chronic inflammatory disorder.

The primary origins of RA drugs derived from biologics and biosimilars include microbial sources, involving bacteria, yeast, and fungi, along with mammalian and other sources. These medications are utilized to address a spectrum of diseases including oncology, immunological, cardiovascular, and hematological disorders. They are manufactured both through outsourced and in-house methods and are made available to patients through prescription and over-the-counter (OTC) channels, including hospital pharmacies, retail outlets, and online pharmacies.

The biologic & biosimilar RA drugs market research report is one of a series of new reports that provides biologic & biosimilar RA drugs market statistics, including biologic & biosimilar RA drugs industry global market size, regional shares, competitors with biologic & biosimilar RA drugs market share, detailed biologic & biosimilar RA drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the biologic & biosimilar RA drugs industry. This biologic & biosimilar RA drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The biologics and biosimilars RA drugs market consists of sales of branded and generic biologics and biosimilar RA drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.